Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:18 2024-12-12 am EST			5-day change	1st Jan Change
88.06 ^CHF	+0.14%		-2.26%	+3.76%

03:00pm	Unsupported price hikes added $815 million to US drug spending in 2023	RE
Dec. 11	Monte Rosa Closes Global License Agreement With Novartis	MT

NOVARTIS AG : Goldman Sachs remains Neutral

October 31, 2024 at 08:52 am EDT

Goldman Sachs analyst James Quigley maintains his Neutral opinion on the stock. The target price has been revised downwards and is now set at CHF 100 as compared to CHF 104 previously.

Latest news about Novartis AG

Unsupported price hikes added $815 million to US drug spending in 2023	09:00am	RE
Monte Rosa Closes Global License Agreement With Novartis	Dec. 11	MT
Swiss Equities Extend Losses; KOF Global Economic Barometers Stable	Dec. 10	MT
Novartis Says Longer-Term Data Highlight Kisqali's Efficacy as Early Breast Cancer Treatment	Dec. 10	MT
Novartis' Breast Cancer Combo Drug Lowers Distant Recurrence Risk in Late-stage Trial	Dec. 10	MT
Novartis: Kisqali effective over the long term, according to data	Dec. 10	CF
Longer-term Novartis Kisqali(R) NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer	Dec. 10	DJ
Novartis Inc. Announces Results from an Updated Analysis of the Pivotal Phase III Natalee Trial of Kisqali®?	Dec. 10	CI
NOVARTIS AG : Deutsche Bank remains Neutral	Dec. 10	ZD
NOVARTIS AG : Jefferies remains Neutral	Dec. 10	ZD
Novartis AG - Special Call	Dec. 09
Novartis: positive long-term data in leukemia	Dec. 09	CF
Novartis Logs Superior Efficacy Results in Longer-term Data for Leukemia Treatment	Dec. 08	MT
Novartis Announces Positive, Long-Term Results from the Pivotal Phase III ASC4FIRST Trial with Scemblix	Dec. 08	CI
Swiss Market Index Ends Week Little Changed; Holcim Shares Down	Dec. 06	MT
Novartis Reports 'Positive' Results From Phase 3 Study of Potential Blood Disorder Therapy	Dec. 06	MT
Novartis: positive data for Fabhalta in HPN	Dec. 06	CF
Novartis' Rare Blood Disorder Drug Improves Hemoglobin Levels in Phase 3b Trial	Dec. 06	MT
New Phase IIIB data shows Novartis Fabhalta(R) improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy	Dec. 06	DJ
Novartis Announces Positive Topline Results from APPULSE-PNH, a Phase IIIB Study Evaluating the Efficacy and Safety of Two-Daily Oral Monotherapy Fabhalta	Dec. 06	CI
NOVARTIS AG : Deutsche Bank remains Neutral	Dec. 05	ZD
US Court Rejects Novartis' Appeal to Block Heart Failure Drug's Generic Version	Dec. 04	MT
Radiant Pharmaceuticals Limited agreed to acquire 60% stake in Novartis Limited from Novartis AG.	Dec. 04	CI
Novartis cannot block generic of best-selling heart drug, US appeals court says	Dec. 04	RE
HSBC Downgrades Novartis to Reduce, Price Target is $95	Dec. 04	MT

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Employees

76,057

Sector

Pharmaceuticals

Calendar

06:30pm - San Antonio Breast Cancer Symposium - Abstract Number - P2-12-02

More about the company